title: [Tri-Regol and its application in gynecological practice].
abstract: One of the most common side effects of the low-dosed estrogen monophasic preparations with selective progestin are breakthrough bleedings and spotting. The aim of the study is to evaluate the contraceptive and therapeutic abilities of the preparation Tri-Regol produced by Gedeon Richter Ltd., Budapest as a suitable alternative to the monophasic preparations. The study includes 29 women at the ages between 19 and 28, non-smokers, who have not given birth. The duration of the observation and the monitoring is 4-6 months (149 cycles altogether). During the first month of administration of the drug, breakthrough bleeding was registered with 5 women (17.2%) and spotting with 2 women (6.8%). During the third month only one woman reported scarce breakthrough bleeding (3.4%). With all the 149 cycles not a single pregnancy was registered. Pearl index--0. With all the patients ovulation was restored within three months after discontinuing the administration of the preparation. The side effects were rare in appearances and tended to decrease and finally disappeared with prolonging the period of administration. The established very good control over the menstrual cycle, the high rate of contraceptive security, the quick restoration of the ovulation accompanied only by rare, mild and discontinuing side effects give us sufficient grounds to recommend the application of the preparation Tri-Regol, product of Gedeon Richter Ltd., Budapest to young women who have not given birth and to women with strongly demonstrated or persisting breakthrough bleedings when treated with low-dosed monophasic preparations.
authors.affiliation: State University Hospital Maichin Dom.
authors.forename: B
authors.initials: B
authors.lastname: Marinov
authors.forename: G
authors.initials: G
authors.lastname: Kolarov
mesh_terms: D000328:Adult; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects*; D008599:Menstruation Disturbances / Q000188:drug therapy; D009644:Norgestrel / Q000009:adverse effects / Q000627:therapeutic use*; D010060:Ovulation / Q000187:drug effects
chemical_list: D003278:Contraceptives, Oral, Hormonal; D003280:Contraceptives, Oral, Synthetic; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination